bluuebunny/crossref_metadata_2025_split huggingface dataset:
9360 Evaluating The More Accurate Indicator Of Kidney Function In Mild Autonomous Cortisol Secretion: EGFR Creatinine Versus EGFR Cystatin
Authors: Rahimi Leili , Saini Jasmine , Atkinson Elizabeth , Achenbach Sara J , Kattah Andrea , Bancos Irina 
Published: October 2024

Abstract
Disclosure: L. Rahimi: None. J. Saini: None. E. Atkinson: None. S. Achenbach: None. A. Kattah: None. I. Bancos: None.
Introduction: Patients with mild autonomous cortisol secretion (MACS) have higher prevalence of cardiovascular comorbidities including chronic kidney disease. However, considering that patients with MACS may have relative skeletal muscle atrophy, it is unclear whether the creatine-based assessment of kidney function is accurate in this population. Objective: To characterize the differences in assessing estimated glomerular filtration rate using cystatin (eGFRcys) versus creatinine (eGFRcre) in patients with MACS versus referent subjects. Methods: Cross-sectional single-center study, 2019-2022. MACS was defined as serum cortisol concentration &gt;1.8 mcg/dL after the 1 mg overnight dexamethasone suppression test (DST). For each patient, eGFRcre, eGFRcys and eGFRcre/eGFRcys ratio were measured and compared between the two groups. Body composition was measured by DXA scan. The Kruskal-Wallis test was used to compare measurements between groups. Result: A total of 37 patients with MACS (median age 59 years (interquartile range, IQR 47-67), 25 (68%) women) and 45 referent subjects (median age 57 years (IQR 51-66), 30 (67%) women) were included. The distribution of BMI, total body fat mass and total body lean mass were similar between the two groups. In the MACS cohort, the median cortisol following 1-mg DST was 3.0 ug/dL (IQR, 2.2-4.0). While assessment of kidney function with eGFRcre showed no differences between patients with MACS and referent subjects (median 85.1 vs 87.0 ml/min/1.73m2, P=0.431), kidney function using eGFRcys was lower in MACS (median 78.0 vs 89.3 ml/min/1.73m2 in referents, P&lt;0.014), resulting also in a higher eGFRcre/eGFRcys ratio (median 1.07 vs 0.97 in MACS vs referents, P=0.053). After adjusting for age, sex, and BMI, a higher 1 mg DST cortisol level in the MACS cohort was associated with a higher eGFRcre/eGFRcys ratio (Spearman correlation coefficient of 0.35, P = 0.042). Lower eGFRcys was associated with higher fat mass (Spearman correlation of -0.26, P = 0.023), and a higher eGFRcre/eGFRcys ratio showed a trend towards lower lean mass (Spearman correlation of -0.20, P = 0.081). Conclusion: Creatinine-based eGFR assessment in patients with MACS underestimates the degree of kidney dysfunction, likely due to underlying skeletal muscle atrophy. eGFRcys is a more accurate indicator of kidney function in patients with hypercortisolism.
Presentation: 6/1/2024
7954 Vitamin D Deficiency Underlies Defective Endometrial Decidualization In Vivo and In Vitro
Authors: Yi MyeongJin , Wang Tianyuan , Jukic Anne Marie , DeMayo Francesco John 
Published: October 2024

Abstract
Disclosure: M. Yi: None. T. Wang: None. A. Jukic: None. F.J. DeMayo: None.
Several epidemiologic studies have reported associations between vitamin D and both menstrual cycles and fertility. Vitamin D signaling occurs most often through the interaction of 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) with its cognate receptor, the transcription factor vitamin D receptor (VDR). This study aims to define the role of vitamin D and VDR on female reproduction and identify vitamin D-mediated signaling. In our studies, preliminary results demonstrate mice on a vitamin D-deficient diet showed a significantly impaired uterine decidualization reaction in response to exogenous hormones. To knockdown VDR expression, human endometrial stroma cells (THESCs) were transfected with either non-targeting control (siNT) or VDR siRNA (siVDR) for 48 h. And, to perform the in vitro decidualization, the cell culture media was replaced to differentiate the cells by treatment with 17β-estradiol (E), medroxyprogesterone acetate (P), and db-cAMP (C) for 72 h. At the 48 h exposure of EPC, the decidual media was replaced with containing 1,25(OH)2D3 or vehicle and cultured for 24 h additionally. Treatment of 1,25(OH)2D3 (ligand) and knockdown of VDR (receptor) in THESCs resulted in an increased expression of the decidualization markers, PRL and IGFBP1. Transcriptomic analysis was then conducted to identify the biological networks regulated by the ligand and receptor in THESCs. THESCs were transfected with either siNT or siVDR for 48 h, and the culture media was replaced with either treatment of 2 nM of 1,25(OH)2D3 or vehicle for an additional 24 h. Differentially expressed genes (DEGs) were affected by the ligand and receptor (N = 626 and 1499, respectively) based on a three-way ANOVA filtered with false discovery rate (FDR)-adjusted p-value&lt;0.05 and fold-change (FC)≥|1.4|. Pathway analyses and predicted upstream regulators were analyzed by Ingenuity Pathways Analysis (IPA), and among the predicted upstream regulators of the DEGs, β-estradiol was predicted as an activator for both. Thus, to test the role of vitamin D in estrogen signaling, THESCs were treated with either EPC or PC for 72 h in total, and at the 48 h exposure, the decidual media was replaced with 1,25(OH)2D3 or vehicle and cultured for 24 h additionally. Removal of estrogen (PC) caused loss of the enhanced expression of decidual markers by 1,25(OH)2D3 that was observed in control EPC-treated cells. In conclusion, Vitamin D signaling modulates human and mouse uterine stromal cell differentiation by modulating the ability of estrogen to stimulate decidualization in endometrial stromal cells, a process critical to establishing pregnancy.
Presentation: 6/2/2024
8815 ANPEP regulates one-carbon metabolism in prostate cancer
Authors: El-Kenawi A , Putney R , Berglund A , Yamoah K 
Published: October 2024

Abstract
Disclosure: A. El-Kenawi: None. R. Putney: None. A. Berglund: None. K. Yamoah: None.
African American men (AAM) experience disproportionately higher rates of both prostate cancer (PCa) incidence and mortality compared to their European American counterparts (EAM). To investigate some of the biological factors which contribute to these disparities, we carried out an unbiased genomic expression analysis of PCa by ancestry using the matched GRID and VANDAAM cohorts. In this analysis, we discovered aminopeptidase N (ANPEP, APN, CD13), to be the most differentially expressed functional gene in both self-identified and ancestry derived AAM compared with EAM. Further computational analyses revealed that ANPEP correlates with signatures of cholesterol transport, estrogen and androgen receptor (AR) signaling. The functional role of ANPEP in regulating cholesterol metabolism and AR signaling remains unclear. Further computational analyses demonstrate that expression of ANPEP predominantly correlates with various amino acid transporters. In addition, comprehensive metabolomic characterization revealed that ANPEP-overexpressing cells exhibit altered level of one-carbon metabolism metabolites. The one-carbon metabolic pathway regulates amino acids homeostasis and epigenetic mechanisms. Metabolomics-based approach to assess the consumption of over 15 amino acids in patient-derived explants validate enrichment of one-carbon metabolism circuits in AAM. Thus, we further investigated whether ANPEP impact high methylation capacity by performing genome-wide methylation profiling in cells. We unraveled that ANPEP overexpression is associated with elevated methylation of DNA. Our future studies will assess whether ANPEP regulation of methylation capacity have an impact on AR binding to DNA.
Presentation: 6/3/2024
12260 Assessing The Impact Of Saliva Collection Devices On Analyte Recovery
Authors: Marshall David , Dolan Megan , Mctaggart Malcolm , Keevil Brian George 
Published: October 2024

Abstract
Disclosure: D. Marshall: None. M. Dolan: None. M. Mctaggart: None. B.G. Keevil: None.
Introduction: Analysis of saliva is gathering momentum, often conveying advantages over regular venepuncture, offering a convenient way of collecting multiple samples throughout the day with relative ease from the comfort of a patient’s home or workplace. The advent of more sensitive mass spectrometry equipment has opened the possibility of measuring analytes previously unsuitable, offering a multitude of steroid hormones for diagnosis and monitoring of a range of endocrine disorders. Traditionally, samples are collected onto a Sarstedt Salivette device comprising of a synthetic swab enclosed within a polypropylene tube. For certain analytes, the Salivette device is known to impede analyte recovery, resulting in the requirement for a passive drool sample which can be difficult and unpleasant to collect for some patients. Methods Previous work has been undertaken showing the SalivaBio Oral Swab (SOS) to have less of an impact on analyte recovery. Here, through addition of low, medium and high spikes and subsequent LC-MS/MS analysis of 19 different steroid hormones (11-dehydrocorticosterone, 11-deoxycorticosterone, 11-deoxycortisol, 11-hydroxyandrostenedione, 11-hydroxytestosterone, 11-ketoandrostenedione, 11-ketotestosterone, 17-hydroxyprogesterone, 18-hydroxycortisol, 18-oxocortisol, 21-deoxycortisol, aldosterone, androstenedione, corticosterone, cortisol, cortisone, dexamethasone, testosterone and tetrahydro11-deoxycortisol) we aimed to assess a broader repertoire of analytes and whether saliva collection devices impact on analyte recovery. Results With an acceptability criterion of 10% difference from baseline passive drool samples, Salivette devices were acceptable for 12 out of 18 analytes, SOS were acceptable for 16 analytes. Both devices were unacceptable for measurement of androstenedione, testosterone and 11-deoxycorticosterone. When 10% is deemed as an acceptable difference, the SOS performs better than the Salivette device for the steroid hormones investigated in this study. This may have implications for research studies, patient diagnosis and monitoring of endocrine disorders where saliva collection devices were previously deemed unacceptable due to issues with analyte recovery.
Presentation: 6/2/2024
12543 Biochemical And Structural Studies Of Human 17-Hydroxysteroid Dehydrogenase Type 1 Mutations Engineered To Convert An NADPH-dependent Reductase To An NAD-dependent Oxidase
Authors: Motl N , Harris K L , Mizrachi D , Auchus R J , Scott E 
Published: October 2024

Abstract
Disclosure: N. Motl: None. K.L. Harris: None. D. Mizrachi: None. R.J. Auchus: None. E. Scott: None.
Background: In intact cells, the hydroxysteroid dehydrogenases (HSDs) strongly favor either NADPH-dependent ketosteroid reduction or NAD+-dependent hydroxysteroid oxidation. For ketosteroid reductases, mutation of the arginine 38 residue in the cofactor-binding domain, which forms a salt-bridge with the 2-phosphate of NADP(H), attenuates the reductive preference but does not eliminate NADPH binding. We sought to engineer mutations of human 17βHSD1 that lack NADP(H) binding, analogous to the oxidative HSDs. Methods: Wild-type 17βHSD1 and mutations of L37 and/or R38 in the cofactor-binding domain were expressed in E. coli and purified to homogeneity in one step. The purified proteins were assayed for NAD+- and NADP-dependent estradiol oxidation to measure cofactor affinity. Crystals were grown in the presence of NAD+ and/or estrone, and structures were determined using molecular replacement. Results: For wild-type 17βHSD1, the Km for NAD+ was 7-times higher than for NADP+ (44 vs 6.2 μM, respectively). Mutations R38D and R38I raised the Km for NAD+ &lt; 4-fold but the Km for NADP+ &gt;60-fold to favor NAD+ utilization. For mutations L37D/R38I and L37D/R38D, the Km for NAD+ was 100-120 μM, but NADP+ could not support catalysis at concentrations up to 4 mM. The crystal structures of 17βHSD1, wild-type and mutations R38D or L37D/R38D soaked with NAD+, were solved to 1.79, 1.75, and 1.80 Å, respectively. All structures displayed a near-identical overall fold. While the NAD density for the mutant structures was much weaker than for the wild type enzymes, some differences in NAD positioning were observed. The R38D mutation had minor NAD repositioning. However, in the L37D/R38D structure the NAD cofactor is repositioned slightly further and 37D is angled towards the cofactor, rather than away from it as observed in the other structures. The positively-charged R38 which interacts with the NADP phosphate oxygen in the wild type enzyme (PDB: 1QYV) is lost in both mutants. Instead the oxygen atoms of both mutated residues orient towards where the cofactor phosphate oxygen would be present, likely interfering with NADP binding and contributing to the observed switch of cofactor preference. Conclusion: Mutation of L37D combined with a second, hydrophobic or negatively-charged substitution at R38 precluded NADP(H) binding and converted 17βHSD1 to a purely oxidative HSD similar to 17βHSD2. NADP(H) exclusion in the L37D/R38D mutant appears to be due to 1) loss of the phosphate-R38 interaction and 2) the position and negatively charged character of oxygen atoms of 37D/38D conflicting with positioning of the positively charged NADP phosphate. Keywords: hydroxysteroid dehydrogenase, nicotinamide cofactor, estrogen, x-ray crystallography
Presentation: 6/2/2024
9273 Characterizing the Genomic Effects of Low-Dose Estrogen in Breast Cancer Cells
Authors: Kim Hyung Bum , Nandu Tulip Sunil , Lee Kraus W 
Published: October 2024

Abstract
Disclosure: H. Kim: None. T.S. Nandu: None. W.L. Kraus: None.
Estrogens are steroid hormones that play a key role in a wide range of physiological and pathological processes. The predominant nuclear receptor for estrogens, estrogen receptor-alpha (ERɑ), functions primarily as a nuclear transcription factor (TF) through ligand-dependent activation by 17β-estradiol (E2), the major naturally-occurring estrogen. The physiological levels of E2 are regulated by production, sequestration, and degradation, which can limit the amount of bioavailable E2. However, many studies examining the genomic effects of E2-regulated signaling in cell-based assays used supraphysiological levels of hormone. While this has allowed us to understand the extremes of E2 signaling, it limits our ability to examine cellular functions which operate at lower hormone concentrations. The genomic actions of ligand-bound ERɑ are mediated through transcriptional enhancer formation and function. Alterations in protein and DNA components dictate different enhancer molecular subtypes that specify distinct regulatory mechanisms and downstream cellular phenotypes. How the amount of available hormone affects these genomic processes is unknown. In order to understand the genomic effects of physiological low-dose levels of E2, we have treated MCF-7 ERɑ-positive human breast cancer cells with a range of E2 concentrations and examined the global regulation of gene expression using a multi-omics approach (RNA-seq, ERɑ ChIP-seq, H3K27ac ChIP-seq, PRO-seq, ATAC-seq). Interestingly, we identified gene sets that are preferentially expressed maximally at picomolar or nanomolar concentrations. We are using these genes sets to explore the mechanisms of estrogen-regulated gene expression at physiologically relevant of E2 concentrations. Analysis of nascent RNA transcription using PRO-seq indicates regulation at the transcriptional level. Preliminary ERɑ chromatin binding assays show that while many loci require high levels of E2 for maximum ERɑ binding, others show maximum ERɑ binding at lower doses of E2. Further analyses show distinct enhancer features, such as chromatin accessibility and H3K27ac enrichment, may play a role in determining the response to E2 dosage. We are now determining the molecular mechanisms of dosage sensitivity using a multipronged approach integrating genomics, molecular biology, and cell-based assays. With these studies, we hope to understand a long overlooked physiological aspect of E2 with a comprehensive and global analysis of signal-dependent genomic responses.
Presentation: 6/3/2024
8530 Characterizing the Genomic Effects of Low-Dose Estrogen in Breast Cancer Cells
Authors: Kim H , Nandu T S , Kraus W L 
Published: October 2024

Abstract
Disclosure: H. Kim: None. T.S. Nandu: None. W.L. Kraus: None.
Estrogens are steroid hormones that play a key role in a wide range of physiological and pathological processes. The predominant nuclear receptor for estrogens, estrogen receptor-alpha (ERɑ), functions primarily as a nuclear transcription factor (TF) through ligand-dependent activation by 17β-estradiol (E2), the major naturally-occurring estrogen. The physiological levels of E2 are regulated by production, sequestration, and degradation, which can limit the amount of bioavailable E2. However, many studies examining the genomic effects of E2-regulated signaling in cell-based assays used supraphysiological levels of hormone. While this has allowed us to understand the extremes of E2 signaling, it limits our ability to examine cellular functions which operate at lower hormone concentrations. The genomic actions of ligand-bound ERɑ are mediated through transcriptional enhancer formation and function. Alterations in protein and DNA components dictate different enhancer molecular subtypes that specify distinct regulatory mechanisms and downstream cellular phenotypes. How the amount of available hormone affects these genomic processes is unknown. In order to understand the genomic effects of physiological low-dose levels of E2, we have treated MCF-7 ERɑ-positive human breast cancer cells with a range of E2 concentrations and examined the global regulation of gene expression using a multi-omics approach (RNA-seq, ERɑ ChIP-seq, H3K27ac ChIP-seq, PRO-seq, ATAC-seq). Interestingly, we identified gene sets that are preferentially expressed maximally at picomolar or nanomolar concentrations. We are using these genes sets to explore the mechanisms of estrogen-regulated gene expression at physiologically relevant of E2 concentrations. Analysis of nascent RNA transcription using PRO-seq indicates regulation at the transcriptional level. Preliminary ERɑ chromatin binding assays show that while many loci require high levels of E2 for maximum ERɑ binding, others show maximum ERɑ binding at lower doses of E2. Further analyses show distinct enhancer features, such as chromatin accessibility and H3K27ac enrichment, may play a role in determining the response to E2 dosage. We are now determining the molecular mechanisms of dosage sensitivity using a multipronged approach integrating genomics, molecular biology, and cell-based assays. With these studies, we hope to understand a long overlooked physiological aspect of E2 with a comprehensive and global analysis of signal-dependent genomic responses.
Presentation: 6/3/2024
7071 Cushing disease presenting with Dilated Cardiomyopathy
Authors: Majeed Hafsa , Nguyen Christina , Galagan Robert , Lovre Dragana 
Published: October 2024

Abstract
Disclosure: H. Majeed: None. C. Nguyen: None. R. Galagan: None. D. Lovre: None.
Background: Hypercortisolism manifests with numerous ways due to the wide distribution of glucocorticoid receptors. Here we describe a case of Cushing’s disease presenting with reversible non-ischemic cardiomyopathy. Case Presentation: A 30-year-old male presented to ER with palpitations, dyspnea, and atypical chest pain. His exam was notable for a BMI of 30.26 kg/m2, HR 76 bpm and BP of 200/110 mm Hg. His EKG revealed Left ventricular hypertrophy. Echocardiogram (ECHO) showed an EF of 25-30% with diffuse hypokinesis. An angiogram demonstrated normal coronary anatomy. He was started on Lisinopril, Carvedilol, and Spironolactone for non-ischemic cardiomyopathy. He also complained of a 40 lb weight gain, loss of libido, hot flashes and breast tenderness. He was referred to endocrinology. Initial evaluation demonstrated total testosterone (TT) of 171 ng/dl (286-1511 ng/dl), FSH 3.8 IU/L (2-12 IU/L), LH 5.6 IU/L (2-9 IU/L) consistent with secondary hypogonadism. Further pituitary workup revealed AM cortisol level 31.22 mcg/dl (4.3-22.4mcg/dl), ACTH 79 pg/ml (7.2 - 63.3pg/ml), IGF-1 257 ng/mL (88-246 ng/mL), Prolactin 23.7 ng/dl (2.1- 17.7ng/dl), TSH 0.54 mIU/l (0.35-3.74mIU/l) and FT4 0.6 ng/dl (0.76-1.46 ng/dl). A 24hr urine cortisol was 167 ug(0-50ug/24h) and midnight salivary cortisol 0.160 ug/dl (&lt;0.010-0.090 ug/dl). An overnight 1mg dexamethasone suppression test (DST) resulted in AM cortisol of 20.95 mcg/dl (&lt;1.8mcg/dl) and 8mg DST cortisol fell from 34 mcg/dl to 4.16 mcg/dl. A pituitary MRI revealed a left 6 mm x 4 mm microadenoma. He was treated with levothyroxine pre-op for central hypothyroidism. He underwent transsphenoidal resection of the pituitary adenoma. Post-op AM cortisol was 1.1 mcg/dl. His steroid withdrawal syndrome was treated with a prolonged course of tapered hydrocortisone. Two months post-op ECHO showed EF of 55-60%. His BP normalized on carvedilol alone. Eighteen months post-op he no longer required any hormone replacement. Repeat ACTH 24.4 pg/ml, Total Testosterone 584ng/dl, TSH 0.57 mIU/l and FT4 0.93 and 24hr urine cortisol was 24ug/dl, MN salivary cortisol &lt;0.10 ug/dl confirming remission of his cushing's disease and resolution of secondary hypogonadism and hypothyroidism. Conclusion: Prolonged hypercortisolism can cause abnormal cardiac remodeling resulting in cardiomyopathy. Surgical remission of Cushing’s disease reverses hypercortisolism which may restore normal cardiac function.
Presentation: 6/2/2024